Table 3.

Level of 25(OH)D in Healthy Subjects and Patients with malabsorption syndrome after 30 day administration of vitamin D3 buccal spray and soft gelatin capsule

Parameters	Mean baseline value in ng/ml	Mean value in ng/ml after 30 day of treatment	Difference of mean	Percentage mean increase from baseline
Healthy Subjects
Soft gelatin Capsule Formulation
Mean	18.69 ± 5.88	22.75 ± 6.75	4.06	21.72 %
Range	9.25, 30.05	12.75, 35.52	2.5, 5.6	15.36, 37.79
n	13	13	13	13
95 % CI	15.14 to 22.24	18.67 to 24.42	3.41 to 4.71	16.42 to 24.42
Buccal Spray Formulation
Mean	18.91 ± 4.3	26.91 ± 5.72	7.995	42.99 %
Range	13.36, 26.82	19.6, 38.5	4.5, 11.67	29.21, 68.71
n	13	13	13	13
95 % CI	16.31 to 21.51	23.45 to 30.36	6.86 to 9.13	37.19 to 48.79
Patients with intestinal malabsorption syndrome
Soft gelatin Capsule Formulation
Mean	11.01 ± 6.43	14.97 ± 9.01	3.965	36.02 %
Range	2.9, 26.5	4.6, 36.89	1.06,10.39	24.62,58.73
n	13	13	13	13
95 % CI	7.12 to 14.89	9.52 to 20.42	2.37 to 5.56	30.42 to 41.62
Buccal Spray Formulation
Mean	10.01 ± 4.29	20.47 ± 7.89	10.46	117.8 %
Range	4.6, 18.85	9.8, 34.64	4.25, 27.44	61.31,381.1
n	13	13	13	13
95 % CI	7.42 to 12.6	15.7 to 25.24	6.89 to 14.03	64.71 to 170.8